Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GOLSEEK-4: golcadomide + rituximab versus investigator's choice in relapsed/refractory follicular lymphoma
2024-519152-82-00Phase 3Authorised
- Sponsor
- Celgene Corporation
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, open-label trial of golcadomide in follicular lymphoma (FL) (2 arms), sponsored by Celgene Corporation. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: authorised.
02
Drugs
golcadomide
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2024-519152-82-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519152-82-00.